Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.
Market Cap | Shares Float | Float Held by Institutions % | Shares Outstanding | Shares Authorized | Institutional Own % |
---|---|---|---|---|---|
6.74 M | 9.14 M | 18.00% | 9.36 M | 200.00 M | 16.59% |
Date of Short Interest by FINRA | Shares Sold Short | Short Float % | Insider Own % | Number Institutions Holding Shares | MVPHS |
---|---|---|---|---|---|
Unavailable | Unavailable | 0 | 7.81% | 43 | $36.47 M |
Stock lockup periods can impact investments by potentially causing increased demand and price appreciation during the lockup period, or increased supply and decreased demand when the lockup ends.
Report Link | Date of Report | Stock Split Info | Stock Split Ratio |
---|---|---|---|
8-K | 26-May-2023 | As a result of the consummation of the Merger, and after giving effect to a previous 70-for-1 reverse stock split of the outstanding shares of common stock of Adamis, effective at the effective time of the Merger (the “Effective Time”), the shares of DMK common stock then outstanding were canceled and automatically converted into and became the right to receive 302,815 shares of Adamis common stock and, with respect to certain former DMK stockholders, 1,941.2 shares of Series E Convertible Preferred Stock (“Series E Preferred”) of the Company. The issuance of the shares of Adamis common stock and Series E Preferred to the former stockholders of DMK in connection with the Merger was approved by the Company’s stockholders at a special meeting of stockholders held on May 15, 2023. | 70-for-1 |
Financial Doc Link | Date of Doc | Cash Equivalents | Burn Rate Operating Activities (monthly) | Operating Expenses (monthly) | Estimated Months Left of Cash |
---|---|---|---|---|---|
10-Q | 15-May-2023 | $3.10 M | $2.98 M | $1.59 M | -3.96 |
As a result of recent cash raise, this company now has an estimated $11.11 M cash with 0.00 months of cash remaining.
Current Assets | Current Liabilities | Working Capital | Total Assets | Total Liabilities | Total Revenues (12 mo) |
---|---|---|---|---|---|
$2.98 M | $12.95 M | -$9.97 M | $9.08 M | $18.60 M | $5.02 M |
Dilutive convertible shares can impact a stock's price by increasing the number of outstanding shares, potentially reducing the value of existing shares and decreasing the stock price.
Stock Warrants can increase share count when exercised. This dilutions affects earnings per share and potentially reduces stock value and impacting investments.
The liquidity and capital resources provides information on the company's cash position, debt levels, and ability to generate cash, indicating its financial stability and potential for growth.
Shelf Registrations can impact a stock's price by increasing the supply of shares available for sale, potentially lowering demand and decreasing stock price, leading to decreased returns on investors.
Shelf Registrations can impact a stock's price by increasing the supply of shares available for sale, potentially lowering demand and decreasing stock price, leading to decreased returns on investors.
Sign up to see if this company has any shelf registrations pending effect
Registration Statements, which provide information on a company's financials and business plans before a public offering, can impact trading by affecting investor perception and demand for the stock, potentially leading to price changes.
Sign up to see if this company has any registration statements
Registration Statements, which provide information on a company's financials and business plans before a public offering, can impact trading by affecting investor perception and demand for the stock, potentially leading to price changes.
Sign up to see if this company has any registration statements pending effect
Company current reports can impact investments by providing important information on material events and changes at the company, affecting the stock price and potential for gains or losses.